EquityFlow
›
Companies
› EG 427
EG 427
Biotech
· FR
Biotech developing non-replicative HSV-1 vector-based gene therapies.
Funding history
Date
Round
Amount
Jul 2023
Series A
French biotech EG 427 added EUR5M to close an EUR18M Series A for its pinpoint gene therapies.
$5.4M
Similar companies in Biotech
Imperagen
Haga Bioscience
Pixelgen Technologies
Gallant
Chai Discovery
SNIPR Biome
Cellbox Labs
Scope Biosciences
GenLumina
Actithera
NUCLIDIUM
Anocca
Explore funding flow on EquityFlow →